Clinical Research

Key Take-Away:

Dexmedetomidine-ketamine combination is a safe alternative for sedation during the cardiac catheterization procedure without the incidence of any hemodynamic or respiratory effects. However, it is associated with some delayed recovery. 

Management of children with congenital heart disease is challenging for anesthesiologists, especially during cardiac catheterization. 

Joshi VS, Kollu SS, Sharma RM. Ann Card Anaesth 2017;20:422-6
18min read    
Key Take-Away:

In patients with gout and major cardiovascular coexisting conditions, febuxostat was non-inferior to allopurinol with respect to rates of adverse cardiovascular events.

Gout is a chronic inflammatory disorder characterised by hyperuricemia, arthropathy, tophus development, and urolithiasis. Gout is reported to be associated with an increased risk of cardiovascular and chronic kidney disease. 

N Engl J Med. 2018 Mar 29;378(13):1200-1210
18min read    
Key Take-Away:

Baricitinib alone or in combination with methotrexate, when used as initial therapyleads to a significant improvement in rheumatoid arthritis as compared to methotrexate alone.

Rheumatoid arthritis (RA) patients often suffer from number of restrictions in daily life due to frequent pain, fatigue, sleep disturbance and functional impairment in work and physical activities. 

Arthritis research & therapy. 2017 Dec;19(1):208.
25min read    
Key Take-Away:

Radiographic findings including joint space narrowing and MRI detected bone marrow lesions, synovitis and effusion are significantly associated with the long term risk of total knee arthroplasty (TKA)  in knee osteoarthritis patients.

Osteoarthritis (OA) is the most chronic joint disorder with an estimated prevalence of 15% worldwide, mainly affecting population aged between 56 to 84. Previous studies reported that aging and obesity were strongly associated with OA.

BMC Musculoskelet Disord. 2017; 18: 510.
16min read    
Key Take-Away:

A biosimilar of etanercept, LBEC0101 posesses an equivalent properties to etanercept (ETN-RP) in terms of clinical efficacy and safety.

Etanercept is a bio-pharmaceutical product obtained through the recombinant DNA technology. It consists of disulfide bond-linked chain of fusion protein and is mainly used for the treatment of autoimmune disorder. 

Annals of the rheumatic diseases. 2017 Dec 19
20min read